{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:08:05Z","timestamp":1790712485859,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cmi.2026.03.035","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:01:43Z","timestamp":1775545303000},"page":"1418-1424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["New antifungals for the treatment of invasive mould disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Nancy N.","family":"Vuong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L.","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin R.","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.03.035_bib1","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2026.03.035_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/tid.70077","article-title":"Invasive fungal disease in solid organ and hematopoietic cell transplant recipients, United States","volume":"27","author":"Gold","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.035_bib3","article-title":"Treatment principles for the management of mold infections","volume":"5","author":"Kontoyiannis","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.cmi.2026.03.035_bib4","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2666-5247(24)00039-9","article-title":"Impact of climate change and natural disasters on fungal infections","volume":"5","author":"Seidel","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2026.03.035_bib5","series-title":"WHO fungal priority pathogens list to guide research, development and public health action","author":"Sati","year":"2022"},{"key":"10.1016\/j.cmi.2026.03.035_bib6","series-title":"Rezzayo (rezafungin) [prescribing information]","year":"2023"},{"key":"10.1016\/j.cmi.2026.03.035_bib7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2026.03.035_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.03.035_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.035_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41586-023-05856-5","article-title":"Structural and mechanistic insights into fungal beta-1,3-glucan synthase FKS1","volume":"616","author":"Hu","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2026.03.035_bib11","series-title":"Brexafemme (ibrexafungerp) [prescribing information]","year":"2022"},{"key":"10.1016\/j.cmi.2026.03.035_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.064","article-title":"871. Oral ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a phase 3 open-label study (FURI)","volume":"9","author":"Thompson","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.035_bib14","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bmcl.2017.06.037","article-title":"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors","volume":"27","author":"Yates","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cmi.2026.03.035_bib15","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.03.035_bib16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/13543784.2022.2086120","article-title":"Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action","volume":"31","author":"Hoenigl","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cmi.2026.03.035_bib17","series-title":"Vivjoa (oteseconazole) [prescribing information]","year":"2024"},{"key":"10.1016\/j.cmi.2026.03.035_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00390-17","article-title":"Prophylactic treatment with VT-1161 protects immunosuppressed mice from rhizopus arrhizus var. arrhizus Infection","volume":"61","author":"Gebremariam","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.03.035_bib19","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1093\/cid\/ciaf185","article-title":"Fosmanogepix for the treatment of invasive mold diseases caused by Aspergillus species and rare molds: a phase 2, open-label study (AEGIS)","volume":"81","author":"Hodges","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.035_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1056\/NEJMoa2308192","article-title":"Neurovascular complications of Iatrogenic Fusarium solani meningitis","volume":"390","author":"Strong","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.03.035_bib21","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/cid\/ciad570","article-title":"Update on outbreak of fungal meningitis among US residents who received epidural anesthesia at two clinics in Matamoros, Mexico","volume":"78","author":"Smith","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.035_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02280-16","article-title":"In vitro and in vivo antifungal profile of a novel and long-acting inhaled Azole, PC945, on Aspergillus fumigatus infection","volume":"61","author":"Colley","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.03.035_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/jof6040373","article-title":"PC945, a novel inhaled antifungal agent, for the treatment of respiratory fungal infections","volume":"6","author":"Murray","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2026.03.035_bib24","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.healun.2020.09.015","article-title":"Successful salvage therapy for fungal bronchial anastomotic infection after -lung transplantation with an inhaled triazole anti-fungal PC945","volume":"39","author":"Pagani","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cmi.2026.03.035_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.690","article-title":"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent","volume":"9","author":"Cass","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.cmi.2026.03.035_bib27","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2026.03.035_bib28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.035_bib29","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/jof8090909","article-title":"GR-2397: review of the novel siderophore-like antifungal agent for the treatment of invasive aspergillosis","volume":"8","author":"Shaw","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2026.03.035_bib31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41586-025-08678-9","article-title":"A polyene macrolide targeting phospholipids in the fungal cell membrane","volume":"640","author":"Deng","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2026.03.035_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/jof7020130","article-title":"Review of T-2307, an investigational agent that causes collapse of fungal mitochondrial membrane potential","volume":"7","author":"Wiederhold","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2026.03.035_bib33","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.01159-07","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine","volume":"52","author":"Mitsuyama","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.03.035_bib34","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.03.035_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00838-20","article-title":"Phase I EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B","volume":"64","author":"Skipper","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.03.035_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106459","article-title":"An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis","volume":"59","author":"Pali\u0107","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2026.03.035_bib37","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/jof9121166","article-title":"Miltefosine: a repurposing drug against mucorales pathogens","volume":"9","author":"Xisto","year":"2023","journal-title":"J Fungi (Basel)"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:50:48Z","timestamp":1787554248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26001734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1198743X26001734"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.03.035","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New antifungals for the treatment of invasive mould disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}